Table of Content

Executive Summary
1 Market Overview
1.1 Cancer Immunotherapy
1.2 Types of Cancer Immunotherapy

2 Market Dynamics
2.1 Drivers
2.1.1 Rising Prevalence of Cancer
2.1.2 Unmet Medical Needs of Cancer Patients
2.1.3 Rising R&D Expenditure in the Immuno-Oncology Segment
2.1.4 Advancement of Precision Medicine in Immuno-oncology
2.2 Restraints
2.2.1 High Cost of Treatment
2.2.2 Adverse Effects of Immunotherapy Treatment
2.3 Opportunities
2.3.1 Development of Targeted Therapy
2.3.2 Development of Healthcare Infrastructure and Reimbursement Policies in Emerging Economies
2.3.3 Combination Therapy

3 Competitive Landscape
3.1 Key Developmental Strategies
3.1.1 Product Approval
3.1.2 Agreements, Collaborations and Partnerships
3.1.3 Clinical Study
3.1.4 Regulatory Designation
3.1.5 Acquisition
3.1.6 Others
3.2 Market Share Analysis

4 Industry Insights
4.1 Regulatory Organizations/ Associations/ Consortiums
4.2 Patent Landscape
4.3 Regulatory Designations

5 Global Cancer Immunotherapy Market (By Product)
5.1 Monoclonal Antibodies
5.2 Checkpoint Inhibitors
5.2.1 CTLA-4 Inhibitors
5.2.2 PD-L1 Inhibitors/ PD-1 Inhibitors
5.3 Cancer Vaccines
5.3.1 Other Cancer Therapies
5.3.1.1 Oncolytic Viruses
5.3.1.2 Adoptive Cell Transfer

6 Global Cancer Immunotherapy Market (by Therapeutic Indication)
6.1 Breast Cancer
6.2 Non-Small Cell Lung Cancer (NSCLC)
6.3 Melanoma
6.4 Colorectal Cancer
6.5 Renal Cell Carcinoma
6.6 Gastric Cancer
6.7 Others

7 Global Cancer Immunotherapy Market (by Region)
7.1 North America
7.1.1 The U.S.
7.1.2 Canada
7.2 Europe
7.2.1 Germany
7.2.2 The U.K.
7.2.3 France
7.2.4 Spain
7.2.5 Italy
7.2.6 Russia
7.2.7 Poland
7.2.8 Austria
7.2.9 Switzerland
7.2.10 Belgium
7.2.11 The Netherlands
7.2.12 Sweden
7.2.13 Finland
7.2.14 Denmark
7.2.15 Ireland
7.2.16 Rest-of-Europe
7.3 Asia-Pacific
7.3.1 China
7.3.2 Japan
7.3.3 India
7.3.4 Australia
7.3.5 South Korea
7.3.6 New Zealand
7.3.7 Malaysia
7.3.8 Bangladesh
7.3.9 Rest-of-Asia-Pacific
7.4 Latin America
7.4.1 Brazil
7.4.2 Mexico
7.4.3 Argentina
7.4.4 Rest-of-Latin-America
7.5 Rest-of-the-World (RoW)
7.5.1 Saudi Arabia
7.5.2 The U.A.E.
7.5.3 South Africa
7.5.4 Israel
7.5.5 Others

8 Company Profiles
8.1 Overview
8.2 Aduro Biotech
8.2.1 Company Overview
8.2.2 Role of Aduro Biotech in Cancer Immunotherapy Market
8.2.3 Financials
8.2.4 Key Insights about the Financial Health of the Company
8.2.5 SWOT Analysis
8.3 Amgen
8.3.1 Company Overview
8.3.2 Role of Amgen Inc in the Cancer Immunotherapy Market
8.3.3 Financials
8.3.4 Key Insights about Financial Health of the Company
8.3.5 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Role of AstraZeneca in Cancer Immunotherapy Market
8.4.3 Financials
8.4.4 Key Insights about Financial Health of the Company
8.4.5 SWOT Analysis
8.5 Bristol-Myers Squibb
8.5.1 Company Overview
8.5.2 Role of Bristol-Myers Squibb in the Cancer Immunotherapy Market
8.5.3 Financials
8.5.4 Key Insights about Financial Health of the Company
8.5.5 SWOT Analysis
8.6 Celgene Corporation
8.6.1 Company Overview
8.6.2 Role of Celgene Corporation in Cancer Immunotherapy Market
8.6.3 Financials
8.6.4 Key Insights about Financial Health of the Company
8.6.5 SWOT Analysis
8.7 DNAtrix Therapeutics
8.7.1 Company Overview
8.7.2 Role of DNAtrix Therapeutics in Cancer Immunotherapy Market
8.7.3 SWOT Analysis
8.8 Eli Lilly and Company
8.8.1 Company Overview
8.8.2 Role of Eli Lilly and Company in Cancer Immunotherapy Market
8.8.3 Financials
8.8.4 Key Insights about Financial Health of the Company
8.8.5 SWOT Analysis
8.9 Gilead Sciences, Inc.
8.9.1 Company Overview
8.9.2 Role of Gilead Sciences, Inc. in Cancer Immunotherapy Market
8.9.3 Financials
8.9.4 Key Insights About the Financial Health of the Company
8.9.5 SWOT Analysis
8.10 Fate Therapeutics
8.10.1 Company Overview
8.10.2 Role of Fate Therapeutics in cancer immunotherapy market
8.10.3 Financials
8.10.4 Key Insights about the Financial Health of the Company
8.10.5 SWOT Analysis
8.11 F. Hoffmann La Roche
8.11.1 Company Overview
8.11.2 Role of F. Hoffmann La Roche in Cancer Immunotherapy market
8.11.3 Financials
8.11.4 Key Insights About the Financial Health of the Company
8.11.5 SWOT Analysis
8.12 JOHNSON & JOHNSON
8.12.1 Company Overview
8.12.2 Role of Johnson & Johnson in Cancer Immunotherapy Market
8.12.3 Financials
8.12.4 Key Insights about the Financial Health of the Company
8.12.5 SWOT Analysis
8.13 Merck & Co., Inc.
8.13.1 Company Overview
8.13.2 Role of Merck & Co, Inc. in Cancer Immunotherapy Market
8.13.3 Financials
8.13.4 Key Insights about the Financial Health of Company
8.13.5 SWOT Analysis
8.14 Novartis AG
8.14.1 Company Overview
8.14.2 Role of Novartis AG in Cancer Immunotherapy Market
8.14.3 Financials
8.14.4 Key Insights about the Financial Health of Company
8.14.5 SWOT Analysis
8.15 Pfizer, Inc.
8.15.1 Company Overview
8.15.2 Role of Pfizer, Inc. in Cancer Immunotherapy Market
8.15.3 Financials
8.15.4 Key Insights about the Financial Health of the Company
8.15.5 SWOT Analysis
8.16 Precision BioSciences, Inc.
8.16.1 Company Overview
8.16.2 Role of Precision BioSciences, Inc. in Cancer Immunotherapy Market
8.16.3 SWOT Analysis
8.17 IOVANCE BIOTHERAPEUTICS, INC.: Snapshot
8.17.1 Company Overview
8.17.2 Role of IOVANCE BIOTHERAPEUTICS, INC. in cancer immunotherapy market

9 Research Scope and Methodology
9.1 Scope of the Report
9.2 Global Cancer Immunotherapy Market Segmentation
9.3 Research Methodology
9.3.1 Primary Research
9.3.2 Secondary Research
9.3.3 Key Data Points from Primary and Secondary Sources
9.3.4 Data Triangulation
9.3.5 Top-Down Approach
9.3.6 Bottom- Up Approach
9.4 Assumptions and Limitations



List of Tables



Table 1: Total Regional Geriatric Population (%), 2015 and 2030
Table 2: Impact analysis of Market Drivers
Table 3: Impact Analysis of Market Restraints
Table 1.1: Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society
Table 2.1: R&D Expense of Major Companies
Table 3.1: Key Company Acquisitions, 2015-2018
Table 4.1: Regulatory Organizations/ Associations.
Table 4.2: Important Regulatory Designations
Table 5.1: List of Monoclonal Antibodies Used in Immunotherapy
Table 5.2: PD-L1 Inhibitors and Their FDA Approved Indication
Table 5.3: PD-1 Inhibitors and Their FDA Approved Indication
Table 6.1: Estimated Incidence, Mortality and Prevalence of Breast Cancer in 2012 (Numbers in thousands)
Table 6.2: Top 25 countries with the highest rates of breast cancer in 2018:
Table 6.3: Estimated Incidence, Mortality, and Prevalence of Lung Cancer (for both sexes) in 2012 (Numbers in thousands)
Table 6.4: NSCLC: 5-Year Survival Rate by Stage
Table 6.5: Age Standardized rate of Colorectal cancer in 2018
Table 6.6: Estimated Incidence, Mortality, and Prevalence of Different Cancer (for both sexes) Worldwide in 2012
Table 6.7: Cervical Cancer Rates: Top 20 Countries in 2018
Table 6.8: Leukaemia: Top 10 Countries with Incidence Rates
Table 7.1: The U.S. Estimated Age-Standardized Incidence Rates in 2018
Table 7.2: Canada Estimated Age-Standardized Incidence Rates in 2018
Table 7.3: Germany Estimated Age-Standardized Incidence Rates in 2018
Table 7.4: The U.K. Estimated Age-Standardized Incidence Rates in 2018
Table 7.5: China Estimated Age-Standardized Incidence Rates in 2018
Table 7.6: Japan Estimated Age-Standardized Incidence Rates in 2018
Table 7.7: India Estimated Age-Standardized Incidence Rates in 2018
Table 7.8: Australia Estimated Age-Standardized Incidence Rates in 2018
Table 7.9: Brazil Estimated Age-Standardized Incidence Rates in 2018
Table 7.10: Mexico Estimated Age-Standardized Incidence Rates in 2018
Table 7.11: Argentina Estimated Age-Standardized Incidence Rates in 2018
Table 8.1: Aduro Biotech: Pipeline Products
Table 8.2: Celgene Product Pipeline
Table 8.3: DNAtrix Therapeutics: Pipeline Products
Table 8.4: Fate Therapeutics: Pipeline Products

List of Figures



Figure 1: Global Cancer Immunotherapy Market, 2017 and 2028
Figure 2: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
Figure 3: Global Cancer Immunotherapy Market (by Product), 2017 and 2028
Figure 4: Global Cancer Immunotherapy Market (by Therapeutic Indication), 2017 and 2028
Figure 5: Global Cancer Immunotherapy Market (by Region), 2017 and 2028
Figure 1.1: Treatment for Cancer
Figure 1.2: Global Cancer Immunotherapy Market, 2017-2028 ($Billion)
Figure 1.3: Key Players Involved in Cancer Immunotherapy
Figure 2.1: Market Dynamics
Figure 3.1: Share of Key Developmental Strategies, 2015-2018
Figure 3.2: Product Approvals, (by Company), 2015-2018
Figure 3.3: Agreements, Collaborations and Partnerships, (by Company), 2015-2018
Figure 3.4: Clinical Study, (by Company), 2015-2018
Figure 3.5: Regulatory Designations, (by Company), 2015-2018
Figure 3.6: Other Strategies (by Company), 2015-2018
Figure 3.7: Market Share Analysis, 2017 and 2018
Figure 4.1: Share of Patents by Ownership, 2015-2018
Figure 5.1: Global Monoclonal Antibodies Market, 2017-2028
Figure 5.2: Global Checkpoint Inhibitors Market, 2017-2028
Figure 5.3: Global Cancer Vaccine Market, 2017-2028
Figure 5.4: Development of CAR-T Therapy
Figure 5.5: Global Cancer Immunotherapy Market for Other Products, 2017-2028
Figure 6.1: Types of Therapeutic Cancer Indications
Figure 6.2: Global Breast Cancer Immunotherapy Market, 2017-2028
Figure 6.3: Global NSCLC Immunotherapy Market, 2017-2028
Figure 6.4: Global Melanoma Immunotherapy Market, 2017-2028
Figure 6.5: Global Colorectal Cancer Immunotherapy Market, 2017-2028
Figure 6.6: Global Renal Cell Carcinoma Immunotherapy Market, 2017-2028
Figure 6.7: Global Gastric Cancer Immunotherapy Market, 2017-2028
Figure 6.8: Global Cancer Immunotherapy Market for Other Cancer Indications, 2017-2028
Figure 7.1: Global Cancer Immunotherapy (by Region)
Figure 7.2: Global Cancer Immunotherapy Market (by Region), 2017-2028
Figure 7.3: North America Cancer Immunotherapy Market
Figure 7.4: North America Cancer Immunotherapy Market, by Country
Figure 7.5: The U.S. Cancer Immunotherapy Market, 2017-2028
Figure 7.6: Canada Cancer Immunotherapy Market
Figure 7.7: Europe Cancer Immunotherapy Market
Figure 7.8: Germany Cancer Immunotherapy Market, 2017-2028
Figure 7.9: The U.K. Cancer Immunotherapy Market, 2017-2028
Figure 7.10: France Cancer Immunotherapy Market, 2017-2028
Figure 7.11: Spain Cancer Immunotherapy Market, 2017-2028
Figure 7.12: Italy Cancer Immunotherapy Market, 2018-2028
Figure 7.13: Russia Cancer Immunotherapy Market, 2018-2028
Figure 7.14: Poland Cancer Immunotherapy Market, 2018-2028
Figure 7.15: Austria Cancer Immunotherapy Market, 2018-2028
Figure 7.16: Switzerland Cancer Immunotherapy Market, 2018-2028
Figure 7.17: Belgium Cancer Immunotherapy Market, 2018-2028
Figure 7.18: The Netherlands Cancer Immunotherapy Market, 2018-2028
Figure 7.19: Sweden Cancer Immunotherapy Market, 2018-2028
Figure 7.20: Finland Cancer Immunotherapy Market, 2018-2028
Figure 7.21: Denmark Cancer Immunotherapy Market, 2018-2028
Figure 7.22: Ireland Cancer Immunotherapy Market, 2018-2028
Figure 7.23: Rest-of-Europe Cancer Immunotherapy Market, 2018-2028
Figure 7.24: Asia-Pacific Cancer Immunotherapy Market, 2017-2028
Figure 7.25: China Cancer Immunotherapy Market, 2017-2028
Figure 7.26: Japan Cancer Immunotherapy Market, 2017-2028
Figure 7.27: India Cancer Immunotherapy Market, 2017-2028
Figure 7.28: Australia Cancer Immunotherapy Market, 2017-2028
Figure 7.29: S. Korea Cancer Immunotherapy Market, 2017-2028
Figure 7.30: New Zealand Cancer Immunotherapy Market, 2017-2028
Figure 7.31: Malaysia Cancer Immunotherapy Market, 2017-2028
Figure 7.32: Bangladesh Cancer Immunotherapy Market, 2017-2028
Figure 7.33: Rest-of-Asia-Pacific Cancer Immunotherapy Market, 2017-2028
Figure 7.34: Latin America Cancer Immunotherapy Market, 2017-2028
Figure 7.35: Latin America Cancer Immunotherapy Market (by Country), 2017-2028
Figure 7.36: Brazil Cancer Immunotherapy Market, 2017-2028
Figure 7.37: Mexico Cancer Immunotherapy Market, 2017-2028
Figure 7.38: Argentina Cancer Immunotherapy Market, 2017-2028
Figure 7.39: Rest-of-Latin-America Cancer Immunotherapy Market, 2017-2028
Figure 7.40: Saudi Arabia Cancer Immunotherapy Market, 2017-2028
Figure 7.41: The U.A.E. Cancer Immunotherapy Market, 2017-2028
Figure 7.42: South Africa Cancer Immunotherapy Market, 2017-2028
Figure 7.43: Israel Cancer Immunotherapy Market, 2017-2028
Figure 7.44: Others Cancer Immunotherapy Market, 2017-2028
Figure 8.1: Aduro Biotech: Overall Financials, 2015-2017
Figure 8.2: Aduro Biotech: Research and Development Expense, 2015-2017
Figure 8.3: Aduro Biotech: SWOT Analysis
Figure 8.4: Amgen Inc: Cancer Immunotherapy Product Portfolio
Figure 8.5: Amgen Inc.: Overall Financials
Figure 8.6: Amgen Inc.: Net Revenue (by Region), 2015-2017
Figure 8.7: Amgen Inc.: R&D Expenditure, 2015-2017
Figure 8.8: Amgen Inc.: SWOT Analysis
Figure 8.9: AstraZeneca PLC: Cancer Immunotherapy Product Portfolio
Figure 8.10: AstraZeneca PLC: Overall Financials, 2015-2017
Figure 8.11: AstraZeneca PLC: Net Revenue (by Business Segment), 2015-2017
Figure 8.12: AstraZeneca PLC: Revenue: Net Revenue (by Regions), 2015-2017
Figure 8.13: AstraZeneca PLC: R&D Expenditure, 2015-2017
Figure 8.14: AstraZeneca PLC: SWOT Analysis
Figure 8.15: Bristol-Myers Squibb: Product Portfolio
Figure 8.16: Bristol-Myers Squibb: Overall Financials
Figure 8.17: Bristol-Myers Squibb: Net Revenue (by Regions), 2015-2017
Figure 8.18: Bristol-Myers Squibb: R&D Expenditure, 2015-2017
Figure 8.19: Bristol-Myers Squibb: SWOT Analysis
Figure 8.20: Celgene Corporation: Overall Financials
Figure 8.21: Celgene Corporation: Net Revenue (by Region), 2015-2017
Figure 8.22: Celgene Corporation: R&D Expenditure, 2015-2017
Figure 8.23: Celgene Corporation: SWOT Analysis
Figure 8.24: DNAtrix Therapeutics: SWOT Analysis
Figure 8.25: Eli Lilly and Company: Product Portfolio
Figure 8.26: Eli Lilly and Company: Overall Financials, 2015-2017
Figure 8.27: Eli Lilly and Company: Net Revenue (by Business Segments), 2015-2017
Figure 8.28: Eli Lilly and Company: Net Revenue (by Regions), 2015-2017
Figure 8.29: Eli Lilly and Company: Research and Development Expenditure, 2015-2017
Figure 8.30: Eli Lilly and Company: SWOT Analysis
Figure 8.31: Gilead Sciences, Inc.: Overall Financials
Figure 8.32: Gilead Sciences, Inc.: Net Revenue (by Region), 2015-2017
Figure 8.33: Gilead Sciences, Inc.: Research and Development Expenditure, 2015-2017
Figure 8.34: Gilead Sciences, Inc.: SWOT Analysis
Figure 8.35: Fate Therapeutics: Overall Financials
Figure 8.36: Fate Therapeutics: Research and Development Expenditure, 2015-2017
Figure 8.37: Fate Therapeutics: SWOT Analysis
Figure 8.38: F. Hoffmann La Roche AG: Product Portfolio
Figure 8.39: F. Hoffmann La Roche: Overall Financials
Figure 8.40: F. Hoffmann La Roche: Net Revenue (by Business Segment), 2015-2017
Figure 8.41: F. Hoffmann La Roche: Net Revenue (by Geographic Regions), 2015-2017
Figure 8.42: F. Hoffmann La Roche: Research and Development Expense, 2015-2017
Figure 8.43: F. Hoffmann La Roche: SWOT Analysis
Figure 8.44: JOHNSON & JOHNSON: Overall Financials, 2015-2017
Figure 8.45: JOHNSON & JOHNSON (by Business Segment), 2015-2017
Figure 8.46: JOHNSON & JOHNSON (by Region), 2015-2017
Figure 8.47: JOHNSON & JOHNSON: Research and Development Expense, 2015-2017
Figure 8.48 JOHNSON & JOHNSON: SWOT ANALYSIS
Figure 8.49: Merck & Co, Inc.: Product Portfolio
Figure 8.50: Merck & Co, Inc.: Overall Financials
Figure 8.51: Merck & Co, Inc. (by Business Segment), 2015-2017
Figure 8.52: Merck & Co, Inc (by Geographic Regions), 2015-2017
Figure 8.53: Merck & Co, Inc.: Research and Development Expense, 2015-2017
Figure 8.54: Merck & Co, Inc.: SWOT Analysis
Figure 8.55: Novartis AG: Cancer Immunotherapy Product Portfolio
Figure 8.56: Novartis AG: Overall Financials (2015-2017)
Figure 8.57: Novartis AG (by Business Segment), 2015-2017
Figure 8.58 Novartis AG (by Geographic Region), 2015-2017
Figure 8.59 Novartis AG: Research and Development Expenditure, 2015-2017
Figure 8.60: Novartis AG: SWOT Analysis
Figure 8.61: Pfizer, Inc.: Cancer Immunotherapy Product Portfolio
Figure 8.62: Pfizer, Inc.: Overall Financials, 2015-2017
Figure 8.63: Pfizer, Inc.: Net Revenue (by Business Segment), 2015-2017
Figure 8.64: Pfizer, Inc.: Net Revenue (by Region), 2015-2017
Figure 8.65: Pfizer, Inc.: Research and Development Expense, 2015-2017
Figure 8.66: Pfizer, Inc.: SWOT Analysis
Figure 8.67: Precision BioSciences, Inc.: SWOT Analysis
Figure 9.1: Global Cancer Immunotherapy Market Segmentation
Figure 9.2: Research Methodology
Figure 9.3: Primary Research Sources
Figure 9.4: Secondary Research Sources
Figure 9.5: Key Data Points from Primary and Secondary Sources
Figure 9.6: Data Triangulation
Figure 9.7: Top-Down Approach: Global Cancer Immunotherapy Market
Figure 9.8: Bottom-up Approach: Global Cancer Immunotherapy Market
Figure 9.9: Assumptions and Limitations